ArticleMolecular biology reports2026
In vitro antibiofilm activity of dermcidin derived peptides against Pseudomonas aeruginosa and Staphylococcus aureus pathogens.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundPseudomonas aeruginosa and Staphylococcus aureus are major opportunistic pathogens capable of developing antibiotic resistance and forming device-associated biofilms, which complicate clinical management. The present study aimed to investigate the antimicrobial and anti-biofilm properties of dermcidin-derived peptides against clinical isolates of these bacteria.
methodsClinical isolates of methicillin-susceptible and methicillin-resistant S. aureus (MSSA and MRSA), as well as carbapenem-susceptible and carbapenem-resistant P. aeruginosa (CSPA and CRPA), were examined for their susceptibility to dermcidin-derived peptides (DCD-1 L, SSL-23, and SSL-25). The in vitro inhibitory activity of the peptides on bacterial adhesion and biofilm formation was evaluated at sub-MIC levels, while their biofilm-disrupting potential was assessed on mature biofilms. Furthermore, the expression of key biofilm-associated and quorum-sensing genes was quantified using qRT-PCR following peptide exposure.
resultsDermcidin-derived peptides markedly inhibited bacterial attachment and biofilm formation at sub-inhibitory concentrations (1/2, 1/4, and 1/8 MIC). In addition, they exhibited strong biofilm eradication activity at higher concentrations (8×-64× MIC). Gene expression analysis revealed significant down-regulation of adhesion- and quorum-sensing-related genes in both S. aureus and P. aeruginosa after treatment.
conclusionThe results suggest that dermcidin-derived peptides, regardless of their net charge, possess potent inhibitory effects on bacterial attachment and biofilm development. These findings highlight their potential as promising therapeutic agents for the prevention and control of biofilm-associated infections.
Indexed as
Identifiers
42377607What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.